NKG2D Ligands in Cancer Immunotherapy: Target or Not?
NKG2D Ligands in Cancer Immunotherapy: Target or Not?
复制标题
DOI：
--
复制
发表时间：
2014-01
期刊：
影响因子：
--
通讯作者：
Jennifer Wu
中科院分区：
文献类型：
--
作者：
Jennifer Wu
In response to DNA damage or pathogenic stress, epithelial cells were induced to express a class of membrane-bound molecules that can be recognized by the NK cell activating receptor NKG2D [1-3]. In human, these molecules include MHC I chain related family of MIC (MICA and MICB) [4], the unique long 16 (UL16)-binding protein (ULBP) or the retinoic acid early transcript (RAET) family[5-8]. Theoretically, expression of these molecules would evoke the anti-tumor immunity through activation of NK cells and costimulation of CD8 T cells, NKT, and subsets of gamma-delta T cells [9]. However, clinical findings of NKG2D ligand expression on tumor cells with disease prognosis are controversy [10-12], which begets the dilemma in whether and how to target NKG2D ligand in cancer immunotherapy.
